Cargando…

Universal Pharmacare in Canada: A Prescription for Equity in Healthcare

Despite progressive universal drug coverage and pharmaceutical policies found in other countries, Canada remains the only developed nation with a publicly funded healthcare system that does not include universal coverage for prescription drugs. In the absence of a national pharmacare plan, a provinc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajizadeh, Mohammad, Edmonds, Sterling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kerman University of Medical Sciences 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093046/
https://www.ncbi.nlm.nih.gov/pubmed/32202091
http://dx.doi.org/10.15171/ijhpm.2019.93
_version_ 1783510223631155200
author Hajizadeh, Mohammad
Edmonds, Sterling
author_facet Hajizadeh, Mohammad
Edmonds, Sterling
author_sort Hajizadeh, Mohammad
collection PubMed
description Despite progressive universal drug coverage and pharmaceutical policies found in other countries, Canada remains the only developed nation with a publicly funded healthcare system that does not include universal coverage for prescription drugs. In the absence of a national pharmacare plan, a province may choose to cover a specific sub-population for certain drugs. Although different provinces have individually attempted to extend coverage to certain subpopulations within their jurisdictions, out-of-pocket expenses on drugs and pharmaceutical products (OPEDP) accounts for a large proportion of out-of-pocket health expenses (OPHE) that are catastrophic in nature. Pharmaceutical drug coverage is a major source of public scrutiny among politicians and policy-makers in Canada. In this editorial, we focus on social inequalities in the burden of OPEDP in Canada. Prescription drugs are inconsistently covered under patchworks of public insurance coverage, and this inconsistency represents a major source of inequity of healthcare financing. Residents of certain provinces, rural households and Canadians from poorer households are more likely to be affected by this inequity and suffer disproportionately higher proportions of catastrophic out-of-pocket expenses on drugs and pharmaceutical products (COPEDP). Universal pharmacare would reduce COPEDP and promote a more equitable healthcare system in Canada.
format Online
Article
Text
id pubmed-7093046
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Kerman University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-70930462020-03-27 Universal Pharmacare in Canada: A Prescription for Equity in Healthcare Hajizadeh, Mohammad Edmonds, Sterling Int J Health Policy Manag Editorial Despite progressive universal drug coverage and pharmaceutical policies found in other countries, Canada remains the only developed nation with a publicly funded healthcare system that does not include universal coverage for prescription drugs. In the absence of a national pharmacare plan, a province may choose to cover a specific sub-population for certain drugs. Although different provinces have individually attempted to extend coverage to certain subpopulations within their jurisdictions, out-of-pocket expenses on drugs and pharmaceutical products (OPEDP) accounts for a large proportion of out-of-pocket health expenses (OPHE) that are catastrophic in nature. Pharmaceutical drug coverage is a major source of public scrutiny among politicians and policy-makers in Canada. In this editorial, we focus on social inequalities in the burden of OPEDP in Canada. Prescription drugs are inconsistently covered under patchworks of public insurance coverage, and this inconsistency represents a major source of inequity of healthcare financing. Residents of certain provinces, rural households and Canadians from poorer households are more likely to be affected by this inequity and suffer disproportionately higher proportions of catastrophic out-of-pocket expenses on drugs and pharmaceutical products (COPEDP). Universal pharmacare would reduce COPEDP and promote a more equitable healthcare system in Canada. Kerman University of Medical Sciences 2019-10-28 /pmc/articles/PMC7093046/ /pubmed/32202091 http://dx.doi.org/10.15171/ijhpm.2019.93 Text en © 2020 The Author(s); Published by Kerman University of Medical Sciences This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Hajizadeh, Mohammad
Edmonds, Sterling
Universal Pharmacare in Canada: A Prescription for Equity in Healthcare
title Universal Pharmacare in Canada: A Prescription for Equity in Healthcare
title_full Universal Pharmacare in Canada: A Prescription for Equity in Healthcare
title_fullStr Universal Pharmacare in Canada: A Prescription for Equity in Healthcare
title_full_unstemmed Universal Pharmacare in Canada: A Prescription for Equity in Healthcare
title_short Universal Pharmacare in Canada: A Prescription for Equity in Healthcare
title_sort universal pharmacare in canada: a prescription for equity in healthcare
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093046/
https://www.ncbi.nlm.nih.gov/pubmed/32202091
http://dx.doi.org/10.15171/ijhpm.2019.93
work_keys_str_mv AT hajizadehmohammad universalpharmacareincanadaaprescriptionforequityinhealthcare
AT edmondssterling universalpharmacareincanadaaprescriptionforequityinhealthcare